Evaluation of the CIB1R peptide derived from the cytoplasmic domain of neprilysin on cell migration in an in vitro model of lung cancer - Summary - MDSpire

Evaluation of the CIB1R peptide derived from the cytoplasmic domain of neprilysin on cell migration in an in vitro model of lung cancer

  • By

  • Carlos Alejandro Martínez-Armenta

  • Horacio Almanza-Reyes

  • Leslie Patrón-Romero

  • Adriana Sampayo-Reyes

  • Juan M. Alcocer-González

  • Reyes Tamez-Guerra

  • Cristina Rodríguez-Padilla

  • Humberto Antonio Salazar-Sesatty

  • Omar Zardain-Medlich-Ducoulombier

  • Francisco González-Salazar

  • Javier Vargas-Villarreal

  • June 23, 2026

  • 0 min

Share

Objective:

To evaluate the effects of CIB1R and related peptides on cell migration and invasion in an in vitro model of non-small cell lung cancer.

Approach:
    Key Findings:
    • CIB1R reduced cell migration and invasion in A549 cells in a dose-dependent manner.
    • The inhibitory effects were also observed with structurally related peptides, indicating non-sequence-specific activity.
    • All peptides demonstrated strong cell-associated fluorescence signals.
    • No significant increase in membrane permeability was detected.
    Interpretation:

    The findings indicate that short cationic peptides derived from the cytoplasmic domain of NEP can modulate cellular behaviors associated with tumor progression in vitro.

    Limitations:
    • The experimental design did not allow definitive discrimination between membrane-associated and intracellular localization.
    • Further studies are required to clarify the molecular basis of these effects and their relevance under physiological conditions.
    Conclusion:

    Initial functional evidence indicates that peptides related to NEP can modulate tumor cell behaviors.

Original Source(s)

Evaluation of the CIB1R peptide derived from the cytoplasmic domain of neprilysin on cell migration in an in vitro model of lung cancer

  • by Carlos Alejandro Martínez-Armenta, Horacio Almanza-Reyes, Leslie Patrón-Romero, Adriana Sampayo-Reyes, Juan M. Alcocer-González, Reyes Tamez-Guerra, Cristina Rodríguez-Padilla, Humberto Antonio Salazar-Sesatty, Omar Zardain-Medlich-Ducoulombier, Francisco González-Salazar, Javier Vargas-Villarreal

  • June 23, 2026

Related Content

Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma

Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis

Durable disease control after multimodal therapy and platinum-based chemotherapy rechallenge in advanced clear cell adenocarcinoma of the urethra with lymph node metastases: a case report